These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15657730)

  • 21. Open-label study of the efficacy and safety of topical treatment with TDT 067 (terbinafine in Transfersome®) in patients with onychomycosis.
    Dominicus R; Weidner C; Tate H; Kroon HA
    Br J Dermatol; 2012 Jun; 166(6):1360-2. PubMed ID: 22136723
    [No Abstract]   [Full Text] [Related]  

  • 22. [Minocycline-induced hyperpigmentation].
    Karrer S; Szeimies RM; Pfau A; Schröder J; Stolz W; Landthaler M
    Hautarzt; 1998 Mar; 49(3):219-23. PubMed ID: 9565791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypomelanosis due to block of melanosomal maturation in amiodarone-induced hyperpigmentation.
    Haas N; Schadendorf D; Hermes B; Henz BM
    Arch Dermatol; 2001 Apr; 137(4):513-4. PubMed ID: 11295949
    [No Abstract]   [Full Text] [Related]  

  • 24. Terbinafine-induced lichenoid drug eruption.
    Zheng Y; Zhang J; Chen H; Lai W; Maibach HI
    Cutan Ocul Toxicol; 2017 Mar; 36(1):101-103. PubMed ID: 26938740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombocytopenia associated with oral terbinafine.
    Grunwald MH
    Int J Dermatol; 1998 Aug; 37(8):634. PubMed ID: 9732018
    [No Abstract]   [Full Text] [Related]  

  • 26. Imipramine-induced facial pigmentation: case report and literature review.
    Metelitsa AI; Nguyen GK; Lin AN
    J Cutan Med Surg; 2005 Dec; 9(6):341-5. PubMed ID: 17016757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Terbinafine : Relevant drug interactions and their management].
    Dürrbeck A; Nenoff P
    Hautarzt; 2016 Sep; 67(9):718-23. PubMed ID: 27474731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral terbinafine and erythema multiforme.
    Todd P; Halpern S; Munro DD
    Clin Exp Dermatol; 1995 May; 20(3):247-8. PubMed ID: 7671425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature.
    Gupta AK; Lynde CW; Lauzon GJ; Mehlmauer MA; Braddock SW; Miller CA; Del Rosso JQ; Shear NH
    Br J Dermatol; 1998 Mar; 138(3):529-32. PubMed ID: 9580815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin.
    Ammoury A; Michaud S; Paul C; Prost-Squarcioni C; Alvarez F; Lamant L; Launay F; Bazex J; Chouini-Lalanne N; Marguery MC
    Arch Dermatol; 2008 Jan; 144(1):92-6. PubMed ID: 18209173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis.
    Kejda J
    Postgrad Med; 1999 Jul; Spec No():12-5. PubMed ID: 10492661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination treatment of oral terbinafine with topical terbinafine and 10% urea ointment in hyperkeratotic type tinea pedis.
    Shi TW; Zhang JA; Zhang XW; Yu HX; Tang YB; Yu JB
    Mycoses; 2014 Sep; 57(9):560-4. PubMed ID: 24697872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two cases of acute generalized exanthematous pustulosis related to oral terbinafine and an analysis of the clinical reaction pattern.
    Eyler JT; Squires S; Fraga GR; Liu D; Kestenbaum T
    Dermatol Online J; 2012 Nov; 18(11):5. PubMed ID: 23217946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dark grey hyperpigmentation on the face and neck. Diagnose: Minocycline-induced hyperpigmentation type III].
    Wienrich BG; Bertsch HP; Schön MP; Emmert S
    J Dtsch Dermatol Ges; 2010 Jul; 8(7):544-6. PubMed ID: 20642719
    [No Abstract]   [Full Text] [Related]  

  • 35. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.
    Baran R; Sigurgeirsson B; de Berker D; Kaufmann R; Lecha M; Faergemann J; Kerrouche N; Sidou F
    Br J Dermatol; 2007 Jul; 157(1):149-57. PubMed ID: 17553051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial.
    Warshaw EM; Fett DD; Bloomfield HE; Grill JP; Nelson DB; Quintero V; Carver SM; Zielke GR; Lederle FA
    J Am Acad Dermatol; 2005 Oct; 53(4):578-84. PubMed ID: 16198776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
    Avner S; Nir N; Henri T
    J Dermatolog Treat; 2005; 16(5-6):327-30. PubMed ID: 16428154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of terbinafine 1% cream on seborrhoeic dermatitis.
    Gündüz K; Inanir I; Sacar H
    J Dermatol; 2005 Jan; 32(1):22-5. PubMed ID: 15841656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute generalized exanthematous pustulosis associated with terbinafine: a case report.
    Turan H; Acer E; Erdem H; Uslu E; Aliagaoglu C
    Cutan Ocul Toxicol; 2013 Oct; 32(4):325-6. PubMed ID: 23432048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What could be expected after fifteen years of amiodarone therapy?
    Radman M; Tomas D; Situm M; Solter M
    Eur J Dermatol; 2008; 18(2):202-3. PubMed ID: 18424394
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.